Evidence map›Paper›PMID 33713012›Full record

ArticlePharmaceutical research2021

A Comprehensive Assessment of All-Oleate Polysorbate 80: Free Fatty Acid Particle Formation, Interfacial Protection and Oxidative Degradation.

Nidhi Doshi, Jamie Giddings, Lin Luis, Arthur Wu, Kyle Ritchie, Wenqiang Liu, Wayman Chan, Rosalynn Taing, Jeff Chu, Alavattam Sreedhara and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Oxidation of polysorbates - An underestimated degradation pathway?International journal of pharmaceutics: X · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Nidhi Doshi *Pharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA. doshin1@gene.com.ORCID http://orcid.org/0000-0002-7553-1864
Jamie Giddings *Pharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Lin LuisPharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Arthur WuPharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Kyle RitchiePharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Wenqiang LiuPharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Wayman ChanAnalytical Operations, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Rosalynn TaingPharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Jeff ChuAnalytical Operations, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Alavattam SreedharaPharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Aadithya KannanPharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Pervina KeiPharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Ian ShiehPharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Tobias GrafPharma Technical Development Analytics, Roche Diagnostics GmbH, Nonnenwald 2, 82377, Penzberg, Germany.
Mark HuPharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Genesys (United States) · USRoche Pharma AG (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEnzymatic polysorbate (PS) degradation and resulting free fatty acid (FFA) particles are detrimental to biopharmaceutical drug product (DP) stability. Different types and grades of polysorbate have varying propensity to form FFA particles. This work evaluates the homogenous all-oleate (AO) PS80 alongside heterogeneous PS20 and PS80 grades in terms its propensity to form FFA particles and other important attributes like interfacial protection and oxidation susceptibility.

methodsFFA particle formation rates were compared by degrading PS using non-immobilized hydrolases and fast degrading DP formulations. Interfacial protection of monoclonal antibodies (mAbs) was assessed by agitation studies in saline using non-degraded and degraded PS. Several antioxidants were assessed for their ability to mitigate AO PS80 oxidation and subsequent mAb oxidation by a 40°C placebo stability study and a 2, 2'-Azobis (2-amidinopropane) dihydrochloride stress model, respectively.

resultsVisible and subvisible particles were significantly delayed in AO PS80 formulations compared with heterogeneous PS20 and PS80 formulations. Non-degraded AO PS80 was less protective of mAbs against the air-water interface compared with heterogeneous PS20. Interfacial protection by AO PS80 improved upon degradation owing to high surface activity of FFAs. Diethylenetriaminepentaacetic acid (DTPA) completely mitigated AO PS80 oxidation unlike L-methionine and N-Acetyl-DL-Tryptophan. However, DTPA did not mitigate radical mediated mAb oxidation.

conclusionAO PS80 is a promising alternative to reduce FFA particle formation compared with other PS types and grades. However, limitations observed here---such as lower protection against interfacial stresses and higher propensity for oxidation---need to be considered in assessing the risk/benefit ratio in using AO PS80.

Indexed as

Antibodies, MonoclonalDrug CarriersDrug CompoundingDrug StabilityFatty Acids, NonesterifiedHydrolysisMethionineOleic AcidOxidation-ReductionOxidative StressParticle SizePolysorbatesTryptophanAntibodies, MonoclonalDrug CarriersFatty Acids, NonesterifiedMethionineN-acetyltryptophanOleic AcidPolysorbatesTryptophanfree fatty acidsmonoclonal antibodiespolysorbate hydrolysispolysorbate oxidationvisible particles

Identifiers

PMID33713012
OpenAlexW3134813405

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.